Article Per Year (5 Year)
p-Index From 2021 - 2026
6.29
P-Index
This Author published in this journals
All Journal Jambi Medical Journal : Jurnal Kedokteran dan Kesehatan Jurnal Ilmu Kedokteran (Journal of Medical Science) Jurnal Kesehatan Andalas Global Medical and Health Communication Biomedical Journal of Indonesia Jurnal Profesi Medika: Jurnal Kedokteran dan Kesehatan Jurnal Penelitian Pendidikan IPA (JPPIPA) Window of Health : Jurnal Kesehatan Majalah Kedokteran Andalas Majalah Patologi Indonesia Bioscientia Medicina : Journal of Biomedicine and Translational Research Majalah Kedokteran Neurosains Human Care Journal Indonesian Journal of Clinical Pathology and Medical Laboratory (IJCPML) Jurnal Ners Science Midwifery Nusantara Hasana Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Cermin Dunia Kedokteran Jurnal Ilmu Kesehatan Indonesia (JIKSI) Journal of Pharmaceutical and Sciences. Neurona
Yuliarni Syafrita
Department Of Neurology, Faculty Of Medicine, Universitas Andalas, Padang, Indonesia.
Agriculture, Biological Sciences & Forestry Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Dentistry Economics, Econometrics & Finance Education Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Nursing Physics Public Health Veterinary

Published : 74 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 74 Documents
Search

 4   5   6   7   8 
Plasma pTau181 dan Gejala Neuropsikiatri pada Demensia Alzheimer: Sebuah Studi Cross-Sectional Fadhilah, Nailatul; Syafrita, Yuliarni; Susanti, Restu; Indra, Syarif; Susanti, Lydia; Putri, Fanny Adhy
Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 4 (2025)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v8i4.1143

Abstract

Alzheimer’s disease is the leading cause of dementia, marked by progressive cognitive decline and neuropsychiatric disturbances collectively known as behavioral and psychological symptoms of dementia (BPSD). Plasma phosphorylated tau at threonine-181 (pTau181) has emerged as a minimally invasive biomarker of tau-related neurodegeneration, but its association with BPSD remains uncertain. This study investigated the relationship between plasma pTau181 levels and BPSD in Alzheimer’s dementia. An analytical observational study with a cross-sectional design was conducted in patients clinically diagnosed with predefined eligibility criteria. Plasma pTau181 concentrations were measured using enzyme-linked immunosorbent assay (ELISA), while BPSD was assessed using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Statistical analyses were performed to examine associations between plasma pTau181 and BPSD status. Plasma pTau181 levels ranged from 4.32 to 97.23 pg/mL, with a median plasma pTau181 level of 19.29 pg/mL (IQR: 11.81-25.05) in patients without BPSD and 20.67 pg/mL (IQR: 11.81-43.41) in those with BPSD. No significant differences in pTau181 levels were observed between patients with and without BPSD (p = 0.310). These findings suggest that plasma pTau181 may not be directly related to the presence of BPSD in Alzheimer’s dementia. While plasma pTau181 remains a promising biomarker of tau pathology, its predictive value for neuropsychiatric symptoms appears limited. Longitudinal studies are needed to explore its role in BPSD pathophysiology further.
Study Analysis of Serum Phosphorylated Tau (P-Tau) Levels with Severity and Outcome in Traumatic Brain Injury Patients: A Single Center Observational Study at Dr. M. Djamil General Hospital, Padang, Indonesia Istiqomah; Syafrita, Yuliarni; Fanny Adhy Putri; Syarif Indra; Restu Susanti; Reno Bestari
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 9 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i9.1060

Abstract

Background: Traumatic brain injury (TBI) is a global health problem that can cause death and disability in people of productive age. The diagnosis and assessment of TBI severity currently still rely on clinical examination and neuroimaging. However, limited access and cost of neuroimaging are obstacles in many health facilities. Therefore, blood-based biomarkers are needed that can help the diagnosis and prognosis of TBI. Phosphorylated Tau (p-tau) is a potential biomarker that can be measured in serum. This study aims to assess the relationship between serum p-tau levels and severity and outcome in TBI patients. Methods: This research is a comparative study with a cross-sectional design involving 70 TBI patients who came to the emergency room (ER) of Dr. M. Djamil General Hospital Padang. TBI severity was assessed using the Glasgow coma scale (GCS) and grouped into mild (GCS 13-15) and moderate to severe (GCS 3-12). Outcomes were assessed using the Glasgow outcome scale (GOS) and grouped into good (GOS 4-5) and poor (GOS 1-3). Serum p-tau levels were measured using the ELISA method. Data analysis was carried out using SPSS. Results: The median serum p-tau level in the mild TBI group was 165.84 ng/L (IQR 126.18-463.85), while in the moderate to severe TBI group, it was 177.68 ng/L (IQR 87.62-591 .93). There was a significant difference between serum p-tau levels in the mild and moderate to severe TBI groups (p=0.029). The median serum p-tau level in the good outcome group was 167.21 ng/L (IQR 87.62-463.85), while in the poor outcome group it was 187.04 ng/L (IQR 137.75-591.93). There was a significant difference between serum p-tau levels in the good and bad outcome groups (p=0.014). Conclusion: Serum p-tau levels have a significant relationship with severity and outcome in TBI patients. Elevated serum p-tau levels are associated with increased severity of TBI and poor outcomes. Further research is needed to confirm these findings and explore the potential of p-tau as a biomarker in TBI management.
Serum High Mobility Group Box 1 (HMGB1) Protein Levels and Cognitive Function in Epilepsy Patients: A Cross-Sectional Study Rahmi Ulfa; Syafrita, Yuliarni; Lydia Susanti
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 9 No. 2 (2025): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v9i2.1183

Abstract

Background: Epilepsy is a neurological disease with a high incidence rate. Cognitive decline is one of the consequences of recurrent seizures. Neuroinflammation is closely related to the development of epilepsy and cognitive impairment. An increase in the expression and translocation of High Mobility Group Box 1 (HMGB1) from the nucleus to the extracellular space has been observed in epilepsy patients and experimental animal models. This study aimed to investigate the relationship between serum HMGB1 levels and cognitive function in epilepsy patients. Methods: This cross-sectional observational study involved 45 epilepsy patients. Cognitive function was assessed using the Indonesian version of the Montreal Cognitive Assessment (MoCA-Ina), and serum HMGB1 levels were measured using the ELISA technique. The relationship between cognitive function and HMGB1 levels was analyzed using the Kruskal-Wallis test, with a significance level set at p < 0.05. Results: The mean age of the participants was 28.5 years, with a higher proportion of females. The mean serum HMGB1 level was 22.6 ng/ml. No significant relationship was found between serum HMGB1 levels and cognitive function in epilepsy patients (p = 0.188). Conclusion: Serum HMGB1 protein levels were not associated with cognitive function in this sample of epilepsy patients.
The Relationship Between Serum Calprotectin Levels and Severity in Myasthenia Gravis Patients at Dr. M. Djamil Hospital Padang Lestari, Novia Riza; Susanti, Lydia; Syafrita, Yuliarni; Susanti, Restu; Bestari, Reno; Sutia, Dedi
Jurnal Ners Vol. 10 No. 1 (2026)
Publisher : Universitas Pahlawan Tuanku Tambusai

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31004/jn.v10i1.51684

Abstract

Myasthenia Gravis (MG) is an autoimmune disorder characterized by skeletal muscle weakness resulting from impaired neuromuscular transmission, primarily caused by autoantibodies directed against acetylcholine receptors. Excessive immune activation in MG triggers the release of inflammatory mediators, one of which is calprotectin — a protein complex of S100A8/A9 that is released by neutrophils and monocytes during the inflammatory process. Elevated levels of calprotectin have been reported in various autoimmune diseases; however, the relationship between serum calprotectin concentration and disease severity in MG, based on the Myasthenia Gravis Foundation of America (MGFA) classification, has not been extensively investigated. The objective of this study was to determine the association between serum calprotectin levels and disease severity in patients with MG. This study employed a cross-sectional design involving 23 MG patients receiving treatment at Dr. M. Djamil Hospital, Padang, from May to July 2025. Serum calprotectin levels were measured using the ELISA method, while MG severity was assessed using the MGFA scoring system. Statistical analyses were performed using SPSS version 27.0, with a significance level set at p < 0.05. The results of this study showed that serum calprotectin levels in patients with Myasthenia Gravis (MG) tended to be higher than in the healthy population; however, there was no significant association with the Myasthenia Gravis Foundation of America (MGFA) severity classification (p = 0.276).
Co-Authors Adang Bachtiar Afriyeni Sri Rahmi Ahmad, Baihaqi Alya Ramadhini Andi Fadilah Yusran Andy, Marfri Anggi Anugerah Basir ATTIYA ISTARINI Basjiruddin Ahmad Bestari, Reno Cintya Agreayu Dinata Darwin Amir Darwin Amir Darwin Amir, Darwin Dedi Sutia Dhiang Mulia Syofiadi Djong Hon Tjong Dwi Sri Rejeki Dwitya Elvira, Dwitya Elsi Rahmadhani Hardi Elvia Fataya Ennesta Asri Erdanela Setiawati Eva Chundrayetti Eva Decroli Fadel Muhammad Fadrian, Fadrian Fanny Adhy Putri Fitra Ermila Basri Gunawan Septa Dinata Haiga, Yuri Harun Harnavi Hauda El Rasyid Hendra Permana Husni Minanda Fikri Indra, Syarif Iqbal Al Rasyid Istiqomah Jabbar, Ridho Ahmad Karina Prasasti Helhid Kurniawan, Yoga Setia Lestari, Novia Riza Lydia Susanti Lydia Susanti Lydia Susanti Lydia Susanti Lydia Susanti, Lydia M Hasan Machfoed Marfri Andy Marliana, Lesti Meldayeni Busra Mubarak, M. Dzaky Muhammad Farhan Khadaffi Mustafa Noer Nailatul Fadhilah Nela Novita Sari Netti Suharti Nora Fitri Nora Fitri Novi Yudia Nur Indrawati Lipoeto Nur Indrawaty Lipoeto Nurhayati Nurhayati Nurvalinda, Nurvalinda Pitra, Dian Ayu Hamama Putri, Fanny Adhy Rahmi Ulfa Rasyid, Hauda El Ratna D Siregar Rauza Sukma Rita Reno Bestari Reno Bestari Restu Susanti Rika Susanti Rika Susanti Rini Gusya Liza, Rini Gusya Rizanda Machmud Rizki Muhammad Rananda RR. Ella Evrita Hestiandari Russilawati, Russilawati Salmiah Agus Sukri Rahman Susila Sastri Susila Sastri Sutia, Dedi Syahrul, Muhammad Zulfadli Syarif Indra Syarif Indra Trya Mia Intani Widia Rahmawati Yantri Maputra Yanwirasti Yanwirasti Yaumi Faiza Yoga Setia Kurniawan Yulia Trisna